Erie, PANCT06401044Now EnrollingIRB Ready

Thyroid Eye Disease Clinical Trial in Erie, PA

Access cutting-edge thyroid eye disease treatment through this clinical trial at a research site in Erie. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Erie location

Preparing your pre-screening questions…

Expert Care in Erie

Access thyroid eye disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related thyroid eye disease treatment provided free

Apply for This Erie Location

Check if you qualify for this thyroid eye disease clinical trial in Erie, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Erie

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Erie site if eligible
  4. 4Begin participation

About This Thyroid Eye Disease Study in Erie

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

for Part A/Phase 1 only:
Participant has provided informed consent before initiation of any study-specific activities/procedures.
Male or female aged 18 to 55 years (Part A).
Female participants must be of non-childbearing potential.
Body mass index (BMI) between 18 and 30 kg/m\^2, inclusive, at screening.
The participant has adequate venous access and can receive intravenous (IV) therapy.
The participant is considered by the investigator or designee to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead electrocardiogram (ECG) results, and physical examination findings at screening.
Healthy Japanese participants in cohort 4 only. Japanese participants must meet all the following as confirmed by interview: Descendants of 4 ethnic Japanese grandparents who were born in Japan; Both parents are ethnic Japanese who were born in Japan; Hold a Japanese passport or identity papers; Have lived outside Japan for less than 10 years at the time of screening and lifestyle including diet has not changed significantly since leaving Japan. Inclusion criteria for Part B/Phase 2 only:
Male or female aged 18 to 65 years.
Moderate-to-severe active TED.
The participant had onset of active TED within 15 months prior to baseline.
Clinical diagnosis of Graves' disease associated with active TED with a Clinical Activity Score (CAS)≥3 for the most severely affected eye at screening and baseline.
Proptosis ≥18mm in the study eye at baseline.
Participants with baseline subjective binocular diplopia score \>0.
Does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the trial.

Exclusion Criteria

for Part A and Part B:
Malignant condition in the past 12 months or major surgery within 8 weeks or plans to have an elective surgery from screening through end of study.
Active liver or kidney disfunction at screening.
Positive test for hepatitis B/C or Human immunodeficiency virus (HIV) serology at screening.
Glycated hemoglobin (HbA1c) \> 6.5% and/or fasting glucose levels\> 126 mg/dL (\> 7 mmol/L) at screening.
Use of any steroid (IV, oral, steroid eye drops) within 3 weeks prior to the first dose. Steroids cannot be initiated during the trial. Exceptions include topical and inhaled steroids and steroids used to treat injection related reactions or short course of steroid for asthma control.
Known hypersensitivity to teprotumumab or any other monoclonal antibody products.
History of substance abuse within 12 months before screening.
Donated blood, or had significant blood loss, or received a transfusion of any blood or blood products within 60 days prior to day 1 dosing or received a plasma donation within 7 days prior to day 1 dosing. Exclusion criteria for PartA/Phase 1 only • Blood pressure or ECG abnormalities at screening. Exclusion criteria for Part B/Phase 2 only:
Use of any steroid or other non-steroid immunosuppressive agent, monoclonal antibody, within 3 months prior to the first injection of study drug.
Use of teprotumumab or any other IGF-1R inhibitor.
Prior orbital irradiation or decompression in the study eye.
History or existing inflammatory bowel disease (ulcerative colitis or Crohn's disease). Other protocol-defined inclusion/exclusion criteria apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Erie?

Yes, this clinical trial (NCT06401044) has an active research site in Erie, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Thyroid Eye Disease Treatment Options in Erie, PA

If you're searching for thyroid eye disease treatment options in Erie, PA, this clinical trial (NCT06401044) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Erie research site is actively enrolling participants for this clinical trial. You'll receive care from experienced thyroid eye disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all thyroid eye disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Erie, PA

See all ankylosing spondylitis clinical trials recruiting in Erie — not just this study.

Browse Ankylosing Spondylitis Trials in Erie →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Erie?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Erie, PA